-
Journal of Receptor, Ligand and Channel Research
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Autoantibodies, human Fcγ receptors, and autoimmunity
Review
(4097) Views (880) Full article downloads
Authors: Margherita Sisto, Sabrina Lisi, Simona D’Amore, et al
Published Date November 2009
Volume 2009:2 Pages 45 - 57
DOI: http://dx.doi.org/10.2147/JRLCR.S6947
Margherita Sisto1,3, Sabrina Lisi1,3, Simona D’Amore2, Massimo D’Amore2
1Department of Human Anatomy and Histology, Cell Biology Section, 2Department of Internal Medicine and Public Medicine, Rheumatology Section, University of Bari Medical School, Bari, Italy; 3The first two authors have equal contribution in this work and both are equally considered the first authors
Abstract: Receptors for the Fc fragment of immunoglobulin G (FcγRs) represent the link between the humoral and cellular immune responses. In humans, three different types of FcγRs belonging to the immunoglobulin gene superfamily, have been identified; FcγRI (cluster of differentiation (CD64), FcγRII (CD32) and FcγRIII (CD16). FcγRs are important molecules not only to mediate and control the effectors functions of immunoglobulin G antibodies, but they also control the autoimmunity–tolerance balance in the periphery. The development of autoimmune diseases is complex and dependent on multiple genes and environmental factors. A wide range of inflammatory and autoimmune diseases such as vasculitis, glomerulonephritis, and autoimmune hemolytic anemia, seems to be mediated, in part, by FcγRs. Considering that the autoantibodies target intracellularly located antigens, recent findings supposed that, under certain conditions, FcγRs are involved in the penetration of antibodies into cells and FcγRs constitute one of the main effector mechanisms through which autoantibodies exert their action. In this review we concentrate on the role of human FcγRs in autoantibodies penetration and summarize the current knowledge on the structure, ligand-binding capacity, and their role in autoimmunity and pathogenic effect of autoantibodies. These novel insights into antibody FcR interactions might be useful to produce the next generation of improved immunotherapeutic molecules.
Keywords: autoantibodies, FcγReceptors, IgG, adalimumab, salivary gland
Readers of this article also read:
Impact of dyslipidemia on cardiovascular risk stratification of hypertensive patients and association of lipid profile with other cardiovascular risk factors: results from the ICEBERG study
Cuff inflation during ambulatory blood pressure monitoring and heart rate
Radiolucency below the crown of mandibular horizontal incompletely impacted third molars and acute inflammation in men with diabetes
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
The impact of biologics on health-related quality of life in patients with inflammatory bowel disease
NMDA-gated ion channel research and its therapeutic potentials in neurodegenerative diseases: a review
Improvement of adenoviral vector-mediated gene transfer to airway epithelia by folate-modified anionic liposomes
Update on the management of inflammatory bowel disease: specific role of adalimumab
Erratum
- Testimonials
"You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio
- Evolution of a domain conserved in microtubule-associated proteins of eukaryotes
- Is gene activity in plant cells affected by UMTS-irradiation? A whole genome approach
- Discrimination between biological interfaces and crystal-packing contacts
- A network biology approach evaluating the anticancer effects of bortezomib identifies SPARC as a therapeutic target in adult T-cell leukemia cells




